[go: up one dir, main page]

AR031230A1 - Agente terapeutico para la hepatitis c el cual comprende un compuesto de anillo fundido, dicho compuesto de anillo fundido, composicion farmaceutica, inhibidor y agente que lo comprenden, envase comercial que comprende dicha composicion, compuesto de benzimidazol y compuesto de tiazol - Google Patents

Agente terapeutico para la hepatitis c el cual comprende un compuesto de anillo fundido, dicho compuesto de anillo fundido, composicion farmaceutica, inhibidor y agente que lo comprenden, envase comercial que comprende dicha composicion, compuesto de benzimidazol y compuesto de tiazol

Info

Publication number
AR031230A1
AR031230A1 ARP000106947A ARP000106947A AR031230A1 AR 031230 A1 AR031230 A1 AR 031230A1 AR P000106947 A ARP000106947 A AR P000106947A AR P000106947 A ARP000106947 A AR P000106947A AR 031230 A1 AR031230 A1 AR 031230A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
group
substituent
atom
Prior art date
Application number
ARP000106947A
Other languages
English (en)
Inventor
Seizo Hashimoto
K Mizutani
Masanori Yoshida
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2000391904A external-priority patent/JP2001247550A/ja
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR031230A1 publication Critical patent/AR031230A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un agente terapéutico para la hepatitis C, que comprende un compuesto de anillo fundido de la formula [1] o una sal farmacéuticamente aceptable del mismo como un ingrediente activo, donde: una línea punteada es un enlace simple o un enlace doble; G1 es C(-R1) o un átomo de nitrogeno; G2 es C(-R2) o un átomo de nitrogeno; G3 es C(-R3) o un átomo de nitrogeno; G4 es C(-R4) o un átomo de nitrogeno; G5, G6, G8 y G9 son, cada uno independientemente, un átomo de carbono o un átomo de nitrogeno; G7 es C(-R7), un átomo de oxígeno, un átomo de azufre, o un átomo de nitrogeno opcionalmente sustituido por R8; donde R1, R2, R3 y R4 son cada uno, independientemente, (1) un átomo de hidrogeno, (2) alcanoilo C1-6, (3) carboxilo, (4) ciano, (5) nitro, (6) alquilo C1-6 opcionalmente sustituido por 1 a 3 sustituyente(s) seleccionado(s) del siguiente grupo A, grupo A: un átomo de halogeno, un grupo hidroxilo, carboxilo, amino, alcoxi C1-6, alcoxicarbonilo C1-6 y alquilamino C1-6, (7) -COORa1 donde Ra1 es alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad) o aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del siguiente grupo B, grupo B: un átomo de halogeno, ciano, nitro, alquilo C1-6, alquilo C1-6 halogenado, alcanoilo C1-6, -(CH2)r-COORb1, -(CH2)r-CONRb1Rb2, -(CH2)r-NRb1Rb2, -(CH2)r-NRb1-CORb2, -(CH2)r-NHSO2Rb1, -(CH2)rORb1, -(CH2)r-SRb1, -(CH2)r-SO2Rb1 y -(CH2)r-SO2NRb1Rb2, donde Rb1 y Rb2 son cada uno, independientemente, un átomo de hidrogeno o alquilo C1-6 y r es 0 o un numero entero de 1 a 6, (8) -CONRa2Ra3 donde Ra2 y Ra3 son cada uno, independientemente, un átomo de hidrogeno, alcoxi C1-6 o alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (9) -C(=NRa4)NH2 donde Ra4 es un átomo de hidrogeno o un grupo hidroxilo, (10) -NHRa5 donde Ra5 es un átomo de hidrogeno, alcanoilo C1-6 o alquilsulfonilo C1-6, (11) -ORa6 donde Ra6 es un átomo de hidrogeno o alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (12) -SO2Ra7 donde Ra7 es un grupo hidroxilo, amino, alquilo C1-6 o alquilamino C1-6, o (13) -P(=O)(ORa31)2 donde Ra31es un átomo de hidrogeno, alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad) o aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B; y R7 y R8 son cada uno un átomo de hidrogeno o alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad); el anillo Cy es (1) cicloalquilo C3-8 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del siguiente grupo C, grupo C: un grupo hidroxilo, un átomo de halogeno, alquilo C1-6 y alcoxi C1-6, (2) cicloalquenilo C3-8 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior C, o (3) un resto de formulas [2], [3] o [4] donde u y v son cada uno, independientemente, un numero entero de 1 a 3; el anillo A es (1) arilo C6-14, (2) cicloalquilo C3-8, (3) cicloalquenilo C3-8 o (4) un grupo heterocíclico que tiene 1 a 4 heteroátomo(s) seleccionado(s) de un átomo de oxígeno, un átomo de nitrogeno y un átomo de azufre; R5 y R6 son cada uno, independientemente, (1) un átomo de hidrogeno, (2) un átomo de halogeno, (3) alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad) o (4) -ORa8 donde Ra8 es un átomo de hidrogeno, alquilo C1-6 o aril C6-14-alquilo C1-6; y X es (1) un átomo de hidrogeno, (2) un átomo de halogeno, (3) ciano, (4) nitro, (5) amino, alcanoilamino C1-6, (6) alquilsulfonilo C1-6, (7) alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (8) alquenilo C2-6 opcionalmente sustituido por 1 a 3 sustituyente(s) seleccionado(s) del grupo anterior A, (9) -COORa9 donde Ra9 es un átomo de hidrogeno o alquilo C1-6, (10) -CONH-(CH2)l-Ra10 donde Ra10 es alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), alcoxicarbonilo C1-6 o alcanoilamino C1-6 y l es 0 o un numero entero de 1 a 6, (11) -ORa11 donde Ra11 es un átomo de hidrogeno o alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), o (12) un compuesto de formula [5] donde el anillo B es (1') arilo C6-14, (2') cicloalquilo C3-8 o (3') un grupo heterocíclico (tal como se definio con anterioridad); cada Z es, independientemente, (1') un grupo seleccionado del siguiente grupo D, (2') arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del siguiente grupo D, (3') cicloalquilo C3-8 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del siguiente grupo D, (4') aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del siguiente grupo D, o (5') un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del siguiente grupo D donde el grupo heterocíclico tiene 1 a 4 heteroátomo(s) seleccionado(s) de un átomo de oxígeno, un átomo de nitrogeno y un átomo de azufre; grupo D: (a) un átomo de hidrogeno, (b) un átomo de halogeno, (c) ciano, (d) nitro, (e) alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (f) -(CH2)t-CORa18 (de ahora en adelante, cada t significa independientemente, 0 o un numero entero de 1 a 6), donde Ra18 es (1'') alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (2'') arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B o (3'') un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B donde el grupo heterocíclico tiene 1 a 4 heteroátomo(s) seleccionado(s) de un átomo de oxígeno, un átomo de nitrogeno y un átomo de azufre, (g) -(CH2)t-COORa19 donde Ra19 es un átomo de hidrogeno, alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad) o aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (h) -(CH2)t-CONRa27Ra28 donde Ra27 y Ra28 son cada uno, independientemente, (1'') un átomo de hidrogeno, (2'') alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (3'') arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (4'') aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (5'') un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (6'') alquilo C1-6 heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, donde el alquilo C1-6 heterocíclico es alquilo C1-6 sustituido por un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, tal como se definio con anterioridad, (7'') cicloalquilo C3-8 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, o (8'') cicloalquil C3-8 alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (i) -(CH2)t-C(=NRa33)NH2 donde Ra33 es un átomo de hidrogeno o alquilo C1-6, (j) -(CH2)t-ORa20 donde Ra20 es (1'') un átomo de hidrogeno, (2'') alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (3'') alquenilo C2-6 opcionalmente sustituido (tal como se definio con anterioridad), (4'') alquinilo C2-6 opcionalmente sustituido por 1 a 3 sustituyente(s) seleccionado(s) del grupo anterior A, (5'') arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (6'') aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (7'') un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (8'') alquilo C1-6 heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (9'') cicloalquilo C3-8 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, o (10'') cicloalquil C3-8-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (k) -(CH2)t-O-(CH2)p-CORa21 donde Ra21 es alquilamino C1-6 o un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, y p es 0 o un numero entero de 1 a 6, (l) -(CH2)t-NRa22Ra23 donde Ra22 y Ra23 son cada uno, independientemente, (1'') un átomo de hidrogeno, (2'') alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), (3'') arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (4'') aril C6-14-alquilo C1-6 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B o (5'') alquilo C1-6 heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (m) -(CH2)t-NRa29CO-Ra24 donde Ra29 es un átomo de hidrogeno, alquilo C1-6 o alcanoilo C1-6 y Ra24 es alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B o un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (n) -(CH2)t-NHSO2-Ra25 donde Ra25 es un átomo de hidrogeno, alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B o un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyente(s) seleccionado(s) del grupo anterior B, (o) -(CH2)t-S(O)q-Ra25 donde Ra25 es tal como se definio con anterioridad y q es 0, 1 o 2, y (p) -(CH2)t-SO2-NHRa26 donde Ra26 es un átomo de hidrogeno, alquilo C1-6 opcionalmente sustituido (tal como se definio con anterioridad), arilo C6-14 opcionalmente sustituido por 1 a 5 sustituyente(s) sel
ARP000106947A 1999-12-27 2000-12-27 Agente terapeutico para la hepatitis c el cual comprende un compuesto de anillo fundido, dicho compuesto de anillo fundido, composicion farmaceutica, inhibidor y agente que lo comprenden, envase comercial que comprende dicha composicion, compuesto de benzimidazol y compuesto de tiazol AR031230A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP36900899 1999-12-27
JP2000391904A JP2001247550A (ja) 1999-12-27 2000-12-25 縮合環化合物及びその医薬用途
JP2001193786 2001-06-26
JP2001351537 2001-11-16

Publications (1)

Publication Number Publication Date
AR031230A1 true AR031230A1 (es) 2003-09-17

Family

ID=37075553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106947A AR031230A1 (es) 1999-12-27 2000-12-27 Agente terapeutico para la hepatitis c el cual comprende un compuesto de anillo fundido, dicho compuesto de anillo fundido, composicion farmaceutica, inhibidor y agente que lo comprenden, envase comercial que comprende dicha composicion, compuesto de benzimidazol y compuesto de tiazol

Country Status (17)

Country Link
US (2) US7112600B1 (es)
EP (1) EP1162196A4 (es)
CN (2) CN1623984A (es)
AR (1) AR031230A1 (es)
AU (1) AU763356C (es)
CA (1) CA2363274A1 (es)
CZ (1) CZ20013424A3 (es)
HU (1) HUP0202263A3 (es)
ID (1) ID30204A (es)
IL (1) IL145071A0 (es)
NO (1) NO20014134L (es)
NZ (1) NZ514403A (es)
RU (1) RU2223761C2 (es)
SK (1) SK13752001A3 (es)
TR (1) TR200103147T1 (es)
WO (1) WO2001047883A1 (es)
ZA (1) ZA200107870B (es)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346216B2 (en) * 1999-12-27 2005-12-08 Japan Tobacco Inc. Fused cyclic compounds and medicinal use thereof
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
EP1435955A2 (en) * 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
AU2007229369C1 (en) * 2001-08-07 2010-10-21 Boehringer Ingelheim (Canada) Ltd. Competitive binding assay for identifying inhibitors of HCV polymerase
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US20030134853A1 (en) * 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
EP1487843A4 (en) 2002-03-20 2010-03-10 Metabolex Inc SUBSTITUTED PHENYLACETIC ACIDS
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
EP1511751B1 (en) * 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2004013141A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
WO2004014871A1 (en) * 2002-08-08 2004-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003287160A1 (en) * 2002-10-15 2004-05-04 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7151114B2 (en) 2003-01-09 2006-12-19 Boehringer Ingelheim International Gmbh Use of substituted 2-phenylbenzimidazoles as medicaments
DE10300398A1 (de) * 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
JP2006526663A (ja) 2003-06-04 2006-11-24 ジェネラブス テクノロジーズ インコーポレーティッド 窒素含有ヘテロアリール誘導体
US7199259B2 (en) 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
EP1651631A1 (en) * 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
GB0321003D0 (en) 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
JP5042626B2 (ja) 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド ベンズイミダゾール誘導体：製造及び医薬適用
WO2005030774A1 (en) * 2003-09-26 2005-04-07 Rigel Pharmaceuticals, Inc. Hcv inhibitors and methods of using them
GB0323845D0 (en) * 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
ES2381890T3 (es) * 2003-12-22 2012-06-01 K.U.Leuven Research & Development Compuesto de imidazo[4,5-c]piridina y métodos de tratamiento antiviral
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN103319464A (zh) * 2004-02-20 2013-09-25 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2005115383A2 (en) 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
US7569580B2 (en) 2004-06-03 2009-08-04 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as HCV inhibitors
EP1758453B1 (en) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
CN1972696B (zh) 2004-06-24 2010-08-11 默沙东公司 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
EP1781658A1 (en) * 2004-07-27 2007-05-09 Gilead Sciences, Inc. Imidazoý4,5-d¨pyrimidines, their uses and methods of preparation
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
PT1841765E (pt) 2004-12-21 2009-05-14 Gilead Sciences Inc Anticorpos para mcp-1 humano
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
WO2006117306A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
CN101511352A (zh) * 2005-06-16 2009-08-19 诺瓦提斯公司 包含内酰胺的hcv抑制剂
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
EP1915378A4 (en) 2005-08-12 2009-07-22 Boehringer Ingelheim Int VIRUS POLYMERASE INHIBITORS
US7714131B2 (en) 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
CA2633757A1 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
US7763731B2 (en) 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7589087B2 (en) 2006-03-31 2009-09-15 Janssen Pharmaceutica, N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor
SI2007752T1 (sl) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
ES2361635T3 (es) 2006-05-19 2011-06-20 Scynexis, Inc. Ciclosporinas para el tratamiento y prevención de trastornos oculares.
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
CA2656415C (en) 2006-07-07 2012-05-22 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
US20080051384A1 (en) * 2006-07-14 2008-02-28 Genelabs Technologies, Inc. Antiviral agents
US7662958B2 (en) 2006-07-19 2010-02-16 Rolf Wagner Anti-infective agents
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
KR20090042973A (ko) 2006-08-17 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
CA2664396A1 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as hiv inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2076278B1 (en) 2006-10-24 2015-05-06 Merck Sharp & Dohme Corp. Macrocyclic HCV NS3 protease inhibitors
CA2667266C (en) 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
KR101615500B1 (ko) 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
CN101568538B (zh) 2006-11-15 2012-09-05 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008075103A1 (en) 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP5211078B2 (ja) 2007-03-13 2013-06-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
JP5465666B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
EP2178886A1 (en) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic indole derivatives for the treatment of hepatitis c infections
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
EP2185539A4 (en) * 2007-08-03 2011-07-20 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
US8940688B2 (en) 2007-12-05 2015-01-27 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide HCV serine protease inhibitors
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
UA100436C2 (en) 2008-07-22 2012-12-25 Mepk Шарп Энд Доме Корп. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
CA2733750C (en) 2008-08-11 2016-10-11 Glaxosmithkline Llc Novel adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
AU2009281195A1 (en) 2008-08-11 2010-02-18 Glaxosmithkline Llc Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
EP2358675B9 (en) 2008-11-14 2019-09-11 Theravance, Inc. 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
MX2011007364A (es) 2009-01-09 2012-02-28 Univ Cardiff Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
SG175047A1 (en) * 2009-04-06 2011-11-28 Schering Corp Indole derivatives and methods for antiviral treatment
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
CA2762885A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
US8822515B2 (en) 2009-10-16 2014-09-02 University Of Maryland, Baltimore County Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
CA2782898A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
WO2011087740A1 (en) * 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2534148A1 (en) 2010-02-10 2012-12-19 GlaxoSmithKline LLC Purine derivatives and their pharmaceutical uses
SI2534149T1 (sl) 2010-02-10 2015-02-27 Glaxosmithkline Llc Corporation Service Company 6-amino-2-((1S)-1-metilbutil)oksi)-9-(5-(1-pipridinil)pentil)-7,9- dihidro-8H purin-8-on maleat
EP2545060B1 (en) * 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011276526A1 (en) 2010-06-28 2013-01-10 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
US9382226B2 (en) 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
CA2832459A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
JP2014511875A (ja) 2011-04-13 2014-05-19 メルク・シャープ・アンド・ドーム・コーポレーション ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013009737A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013016491A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AP2014007595A0 (en) * 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
WO2013086133A1 (en) 2011-12-06 2013-06-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
EP2855484A4 (en) * 2012-05-31 2015-12-16 Pharmascience Inc PROTEIN KINASE INHIBITORS
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
SG11201507117XA (en) 2013-03-06 2015-10-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
RU2529679C1 (ru) * 2013-08-08 2014-09-27 Общество с ограниченной ответственностью "Научно-производственное объединение "МедФармСинтез" Способ получения калиевой соли 2-[1-(1,1-диоксотиетанил-3)бензимидазолил-2-тио]уксусной кислоты
KR20160060660A (ko) 2013-10-01 2016-05-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 친화성 크로마토그래피를 위한 및 치료제의 반감기를 연장시키기 위한 화합물
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
CA2938476A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
CN107074852B (zh) 2014-10-14 2019-08-16 生命医药有限责任公司 ROR-γ的二氢吡咯并吡啶抑制剂
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
BR112017009648A2 (pt) 2014-11-13 2017-12-19 Glaxosmithkline Biologicals Sa composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
JP6595208B2 (ja) * 2015-05-01 2019-10-23 日本放送協会 送信装置および受信装置
WO2017005674A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
HK1250032A1 (zh) 2015-12-03 2018-11-23 Glaxosmithkline Intellectual Property Development Limited 作为sting调节剂的环状嘌呤二核苷酸
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
HUE064656T2 (hu) 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
AU2017247798C1 (en) 2016-04-07 2020-08-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US10975287B2 (en) 2016-04-07 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
GB201701087D0 (en) 2017-01-23 2017-03-08 Univ Leuven Kath Novel prodrugs of mizoribine
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CN114829366A (zh) 2019-11-11 2022-07-29 因赛特公司 Pd-1/pd-l1抑制剂的盐及结晶形式
AU2020409429A1 (en) 2019-12-18 2022-06-16 Ctxt Pty Ltd Compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CN114957165A (zh) * 2021-02-26 2022-08-30 清华大学 一种抗病毒化合物及其制备方法和应用
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1584735A (es) 1968-03-20 1970-01-02
CH632628B (de) 1976-07-26 Ciba Geigy Ag Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller.
DE2964427D1 (en) 1978-10-04 1983-02-03 Ciba Geigy Ag Process for the preparation of furanyl-benzazoles
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
FR2674855B1 (fr) * 1991-04-03 1994-01-14 Synthelabo Derives de piperidine, leur preparation et leur application en therapeutique.
JPH0625182A (ja) 1992-07-09 1994-02-01 Kanebo Ltd ベンズイミダゾール誘導体
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
ZA953311B (en) 1994-04-29 1996-10-24 Lilly Co Eli Non-peptidyl tachykinin receptor antagonists
PL319440A1 (en) 1994-09-09 1997-08-04 Wellcome Found Analoques of antiviral nuceosides containing substituted benzimidazoles attached to the carbocyclic ring
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
DK0882718T3 (da) 1995-12-28 2005-12-12 Astellas Pharma Inc Benzimidazolderivater
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
CN1151841C (zh) 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备刺激防御机制或免疫反应的药物中的应用
JP2000511899A (ja) * 1996-06-05 2000-09-12 イーライ・リリー・アンド・カンパニー 抗―ウイルス性化合物群
AU3899097A (en) 1996-08-05 1998-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
DE69814049T2 (de) 1997-02-25 2004-02-19 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
PH11998001073B1 (en) 1997-05-07 2007-07-23 Univ Pittsburgh Inhibitors of protein isoprenyl transferases
JP2001522811A (ja) 1997-11-07 2001-11-20 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ インターフェロン免疫療法
AU3379199A (en) 1998-04-03 1999-10-25 Regents Of The University Of Michigan, The Arabinofuranosyl benzimidazoles as antiviral agents
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con

Also Published As

Publication number Publication date
HUP0202263A2 (hu) 2002-12-28
CZ20013424A3 (cs) 2002-02-13
TR200103147T1 (tr) 2002-06-21
AU2401701A (en) 2001-07-09
EP1162196A4 (en) 2003-04-16
CN1167680C (zh) 2004-09-22
NO20014134D0 (no) 2001-08-24
CA2363274A1 (en) 2001-07-05
AU763356C (en) 2004-08-26
ZA200107870B (en) 2002-09-25
SK13752001A3 (sk) 2002-07-02
US20070032497A1 (en) 2007-02-08
WO2001047883A1 (fr) 2001-07-05
NO20014134L (no) 2001-10-22
RU2223761C2 (ru) 2004-02-20
CN1342145A (zh) 2002-03-27
HUP0202263A3 (en) 2003-02-28
IL145071A0 (en) 2002-06-30
ID30204A (id) 2001-11-15
CN1623984A (zh) 2005-06-08
EP1162196A1 (en) 2001-12-12
NZ514403A (en) 2002-10-25
US7112600B1 (en) 2006-09-26
AU763356B2 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
AR031230A1 (es) Agente terapeutico para la hepatitis c el cual comprende un compuesto de anillo fundido, dicho compuesto de anillo fundido, composicion farmaceutica, inhibidor y agente que lo comprenden, envase comercial que comprende dicha composicion, compuesto de benzimidazol y compuesto de tiazol
AR035543A1 (es) Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR045762A1 (es) Derivados de quinazolina
AR011093A1 (es) Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso.
AR036127A1 (es) Composicion para administracion topica que comprende un inhibidor de interleucina 2 y un agente antimicrobiano y uso de estos ultimos para preparar dicha composicion
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
AR039203A1 (es) Derivados de quinazolina
AP2001002241A0 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
AR043015A1 (es) Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores
AR057986A1 (es) Compuesto heterociclico y su uso farmaceutico
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AR078508A1 (es) Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos
JP2005502621A5 (es)
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
PE20252677A1 (es) Amidas de azolipiridina piridazinona como inhibidores de sos1
AR045819A1 (es) Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20090712A1 (es) Moduladores de la gamma secretasa
AR045694A1 (es) Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal